Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk - PACE-CME

Lowdose NOAC after COVID hospitalization in patients with high thrombotic risk

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
AHA 2024
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
- Chisato Izumi, MD, PhD
New ESC Guidelines for CCS and PAAD
New ESC Guidelines for CCS and PAAD
ESC Congress 2024
New ESC Guidelines for CCS and PAAD
- Pierre Sabouret, MD, PhD
Continuation or interruption of OAC during TAVI?
Continuation or interruption of OAC during TAVI?
ESC Congress 2024
Continuation or interruption of OAC during TAVI?
- Dirk Jan van Ginkel, MD
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
AHA 2023
Results with novel FXI inhibitor in AF set the stage for phase 3 trials
- Christian Ruff, MD